{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Primary+Malignant+Neoplasm+of+Gastrointestinal+Tract&page=2", "query": { "condition": "Primary Malignant Neoplasm of Gastrointestinal Tract", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Primary+Malignant+Neoplasm+of+Gastrointestinal+Tract&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-27T17:10:00.006Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02711137", "title": "Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "INCB057643", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Rucaparib", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 137, "start_date": "2016-05-18", "completion_date": "2019-02-13", "has_results": true, "last_update_posted_date": "2025-10-21", "last_synced_at": "2026-06-27T17:10:00.006Z", "location_count": 16, "location_summary": "Birmingham, Alabama • La Jolla, California • Denver, Colorado + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02711137" }, { "nct_id": "NCT00900302", "title": "OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cancer" ], "interventions": [ { "name": "protein expression analysis", "type": "GENETIC" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "GENETIC", "OTHER", "PROCEDURE" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "120 Years", "sex": "ALL", "summary": "Up to 120 Years" }, "enrollment_count": 98, "start_date": "2005-04", "completion_date": "2011-03", "has_results": false, "last_update_posted_date": "2016-02-10", "last_synced_at": "2026-06-27T17:10:00.006Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00900302" }, { "nct_id": "NCT07118176", "title": "Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anal Carcinoma", "Bladder Carcinoma", "Breast Carcinoma", "Cervical Carcinoma", "Cholangiocarcinoma", "Colorectal Carcinoma", "Esophageal Carcinoma", "Gastric Carcinoma", "Head and Neck Carcinoma", "Hematopoietic and Lymphatic System Neoplasm", "Hepatocellular Carcinoma", "Lung Carcinoma", "Malignant Adrenal Gland Neoplasm", "Malignant Brain Neoplasm", "Malignant Neoplasm of Unknown Primary", "Malignant Solid Neoplasm", "Malignant Testicular Neoplasm", "Malignant Uterine Neoplasm", "Neuroendocrine Neoplasm", "Ovarian Carcinoma", "Pancreatic Carcinoma", "Penile Carcinoma", "Pleural Carcinomatosis", "Primary Peritoneal Carcinoma", "Prostate Carcinoma", "Salivary Gland Carcinoma", "Sarcoma", "Skin Carcinoma", "Solitary Fibrous Tumor", "Thymus Carcinoma", "Thyroid Gland Carcinoma", "Thyroid Gland Medullary Carcinoma", "Urothelial Carcinoma", "Vaginal Carcinoma" ], "interventions": [ { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Fludeoxyglucose F-18", "type": "OTHER" }, { "name": "Gallium Ga 68 FAPi-46", "type": "RADIATION" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "OTHER", "RADIATION" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2025-08-01", "completion_date": "2027-09-07", "has_results": false, "last_update_posted_date": "2025-08-12", "last_synced_at": "2026-06-27T17:10:00.006Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07118176" }, { "nct_id": "NCT00066404", "title": "Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "recombinant adenovirus-hIFN-beta", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": null, "start_date": "2003-04", "completion_date": "2006-01", "has_results": false, "last_update_posted_date": "2020-05-13", "last_synced_at": "2026-06-27T17:10:00.006Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00066404" }, { "nct_id": "NCT00544336", "title": "Family Quality of Life Among Families With a Member Who is a Cancer Patient", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer", "Colorectal Cancer", "Head and Neck Cancer", "Lung Cancer", "Prostate Cancer", "Solid Tumor" ], "interventions": [ { "name": "questionnaire administration", "type": "OTHER" }, { "name": "survey administration", "type": "OTHER" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" } ], "intervention_types": [ "OTHER", "PROCEDURE" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 366, "start_date": "2007-08", "completion_date": "2009-05", "has_results": false, "last_update_posted_date": "2012-09-10", "last_synced_at": "2026-06-27T17:10:00.006Z", "location_count": 3, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00544336" }, { "nct_id": "NCT03452774", "title": "SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cancer, Metastatic", "Cancer", "Cancer of Pancreas", "Cancer of Liver", "Cancer of Stomach", "Cancer Liver", "Cancer of Rectum", "Cancer of Kidney", "Cancer of Esophagus", "Cancer of Cervix", "Cancer of Colon", "Cancer of Larynx", "Cancer, Lung", "Cancer, Breast", "Cancer, Advanced", "Cancer Prostate", "Cancer of Neck", "Cancer of Skin", "Neuroendocrine Tumors", "Carcinoma", "Mismatch Repair Deficiency", "BRCA Gene Rearrangement", "Non Hodgkin Lymphoma", "Leukemia", "Non Small Cell Lung Cancer", "Cholangiocarcinoma", "Glioblastoma", "Central Nervous System Tumor", "Melanoma", "Urothelial Carcinoma", "Bladder Cancer", "Ovarian Cancer", "Endometrial Cancer", "Testicular Cancer", "Breast Cancer", "COVID", "Myelofibrosis", "Myeloproliferative Neoplasm", "Myeloproliferative Disorders", "Follicular Lymphoma", "Mantle Cell Lymphoma", "Marginal Zone Lymphoma", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "Clinical Trial Matching", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Massive Bio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 50000, "start_date": "2018-01-01", "completion_date": "2040-06", "has_results": false, "last_update_posted_date": "2025-10-28", "last_synced_at": "2026-06-27T17:10:00.006Z", "location_count": 67, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 64 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03452774" }, { "nct_id": "NCT00003548", "title": "Aminocamptothecin in Treating Patients With Advanced Cancer of the Peritoneal Cavity", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "aminocamptothecin colloidal dispersion", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "1998-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2011-03-28", "last_synced_at": "2026-06-27T17:10:00.006Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003548" }, { "nct_id": "NCT04771520", "title": "Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anatomic Stage IV Breast Cancer AJCC v8", "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Locally Advanced Malignant Solid Neoplasm", "Locally Advanced Melanoma", "Locally Advanced Primary Malignant Central Nervous System Neoplasm", "Locally Advanced Sarcoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Melanoma", "Metastatic Primary Malignant Central Nervous System Neoplasm", "Metastatic Sarcoma", "Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Prognostic Stage IIIC Breast Cancer AJCC v8", "Prognostic Stage IV Breast Cancer AJCC v8", "Stage IIIC Colorectal Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IV Colorectal Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IVA Colorectal Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Colorectal Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8", "Stage IVC Colorectal Cancer AJCC v8" ], "interventions": [ { "name": "Avapritinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2021-01-20", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-06-11", "last_synced_at": "2026-06-27T17:10:00.006Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04771520" }, { "nct_id": "NCT03329950", "title": "A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Non-small Cell Lung Cancer", "Breast Cancer", "Gastric Cancer", "Renal Cell Carcinoma", "Ovarian Cancer", "Cholangiocarcinoma", "Bladder Urothelial Carcinoma", "Pancreatic Adenocarcinoma", "Colorectal Cancer", "Esophageal Cancer", "Hepatic Cancer", "Head and Neck Cancer", "Primary Peritoneal Cancer", "Fallopian Tube Cancer", "Other Solid Tumors", "Diffuse Large B-cell Lymphoma (DLBCL)", "Mantle Cell Lymphoma", "Indolent B-cell Lymphomas", "Non-Hodgkin Lymphoma", "Follicular Lymphoma", "Lymphoplasmacytic Lymphoma", "Waldenstrom's Disease", "Marginal Zone Lymphoma", "Mucosa Associated Lymphoid Tissue", "Small Lymphocytic Leukemia" ], "interventions": [ { "name": "CDX-1140", "type": "DRUG" }, { "name": "CDX-301", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" }, { "name": "Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celldex Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 132, "start_date": "2017-12-01", "completion_date": "2022-09-13", "has_results": false, "last_update_posted_date": "2024-03-28", "last_synced_at": "2026-06-27T17:10:00.006Z", "location_count": 11, "location_summary": "Scottsdale, Arizona • Atlanta, Georgia • Augusta, Georgia + 7 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03329950" }, { "nct_id": "NCT00073944", "title": "BCX-1777 in Treating Patients With Refractory Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "forodesine hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioCryst Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2003-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-05-30", "last_synced_at": "2026-06-27T17:10:00.006Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00073944" } ] }